Moving the Needle Forward in Cancer Rehabilitation

Commentary
Video

It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.

When looking towards the future, Jessica Cheng, MD, hopes that patients and clinicians will underscore the importance of adding cancer rehabilitation into treatment plans as the field becomes more widespread.

She noted that with the implementation of cancer rehabilitation into treatment strategies, performance status and function can be significantly improved, which may correlate with better outcomes and reduced hospital stays. Cheng, assistant clinical professor in the Department of Supportive Care Medicine at City of Hope, wants the word to spread about this niche area, as it may allow for more informed treatment decisions and serve as an “integral part of the cancer space”.

With her catchphrase of “prehab for all”, she hopes that colleagues will learn more about cancer rehabilitation and what it can mean for their patients. By developing a greater understanding of cancer rehabilitation, practices may help patients navigate their treatment course more easily while aiding their recovery following therapy.


Transcript:

I see the value of rehabilitation medicine in the cancer space as an integral part of the cancer space. My heart’s desire is that every institution that takes care of patients with cancer will recognize the importance of optimizing function and performance status from the beginning and throughout the cancer journey from prehabilitation to rehabilitation. There’s a lot of room for growth there.

My catchphrase recently is “prehab for all”. I want everyone to be armed with this knowledge of what they can do that’s in their control to optimize their abilities for meaningful activities throughout the cancer journey. I hope that oncologists and rehabilitation physicians alike will see that there’s an opportunity with cancer prehabilitation to enable [patients] to get their cancer treatment, get through it better, and recover better. That’s my hope: that this will just spread even more like wildfire than it already is.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content